Sunday, December 23, 2012 12:54:34 PM
Kevetrin is an HDAC-2 and HDAC-6 regulators. HDM2 is an inhibitor.
Kevetrin has several other subordinate activities, such as, regulating c-myc activity, inducing apoptosis, etc.. It has also been seen that Kevetrin has anti-angiogenic properties.
See my earlier post including info from company: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82597857
See progressive post of earlier PR dealing with this: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82732988
Also, see search of FDA website for the other companies trials and you will notice HDM2 isn't listed yet.
http://www.clinicaltrial.gov/ct2/results?term=Ascenta+Therapeutics%2C+Inc&Search=Search
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM